E-viri
PDF
Recenzirano
Odprti dostop
-
Ollivier-Hourmand, I; Lebedel, L; Lecouf, A; Allaire, M; Nguyen, T. T. N; Lier, C; Dao, T
BMC infectious diseases, 07/2020, Letnik: 20, Številka: 1Journal Article
Hepatitis E virus (HEV) may be resistant to immunosuppression reduction and ribavirin treatment in kidney transplant recipients because of mutant strains and severe side effects of ribavirin which conduct to dose reduction. Sofosbuvir efficacy is controversial. Peg-interferon 2 alpha (PEG-IFN) is currently contraindicated due to a high risk of acute humoral and cellular rejection. The present study assessed, for the first time, the effect of PEG-IFN in a kidney transplant recipient infected with HEV. We conclude that prolonged treatment with PEG-IFN in kidney transplant recipients infected with HEV could be considered as a salvage option.
